Correspondence 0001104659-24-000118 from HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma Inc.
Date: Jan. 2, 2024 · CIK: 0001760542 · Accession: 0001104659-24-000118
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276220
Letter
HOOKIPA Pharma Inc.
350 Fifth Avenue, 72nd Floor, Suite 7240
New York, New York
January 2, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: HOOKIPA Pharma Inc.: Registration Statement on Form S-3 filed December 22, 2023 (File No. 333-276220)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), HOOKIPA Pharma Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 4, 2024, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Finnbarr D. Murphy of Goodwin Procter LLP at (212) 459-7257.
Sincerely,
HOOKIPA Pharma Inc.
Show Raw Text
CORRESP
1
filename1.htm
HOOKIPA Pharma Inc.
350 Fifth Avenue, 72nd Floor, Suite 7240
New York, New York
10118
January 2, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: HOOKIPA Pharma Inc.: Registration Statement on Form S-3 filed December 22, 2023 (File No. 333-276220)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Act”), HOOKIPA Pharma Inc. (the “Company”) hereby requests that the
effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 4,
2024, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by
telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company
acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request,
please contact Finnbarr D. Murphy of Goodwin Procter LLP at (212) 459-7257.
Sincerely,
HOOKIPA Pharma Inc.
/s/ Reinhard Kandera
Reinhard Kandera
Chief Financial Officer
cc: Joern Aldag, HOOKIPA Pharma Inc.
Robert Puopolo, Esq., Goodwin Procter LLP
Finnbarr D. Murphy, Esq., Goodwin Procter
LLP